Reactive species
Human;Mouse;Rat
Applications
IF;WB;IHC;ELISA
Antibody type
Polyclonal Antibody
Protein name
Cyclin-dependent kinase inhibitor 1
Immunogen
The antiserum was produced against synthesized peptide derived from human p21 Cip1. AA range:111-160
Specificity
p21 Polyclonal Antibody detects endogenous levels of p21 protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
IF: 1:50-200 Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications.
Purification process
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Other name
CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; p21
Background
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lac
Function
function:May be the important intermediate by which p53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression.,induction:By p53, mezerein (antileukemic compound) and interferon beta.,PTM:Phosphorylation of Thr-145 by Akt or of Ser-146 by PKC impairs binding to PCNA.,similarity:Belongs to the CDI family.,tissue specificity:Expressed in all adult human tissues, with 5-fold lower levels observed in the brain.,
